<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01899261</url>
  </required_header>
  <id_info>
    <org_study_id>2010-326</org_study_id>
    <secondary_id>2010-326</secondary_id>
    <secondary_id>P30CA013330</secondary_id>
    <nct_id>NCT01899261</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>A Pilot Study of Stereotactic Liver Irradiation for Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies stereotactic body radiation therapy in treating patients
      with liver cancer that cannot be removed by surgery. Stereotactic radiation therapy may be
      able to send x-rays directly to the tumor and cause less damage to normal tissue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate feasibility and safety of stereotactic body radiation therapy (SBRT) of the
      liver for treatment of hepatocellular carcinoma (HCC).

      SECONDARY OBJECTIVES:

      I. To evaluate radiographic local response, local control and time to local progression
      (TTLP) of treated lesions in HCC patients after liver SBRT.

      II. To evaluate overall survival (OS) and cancer specific survival (CSS) in HCC patients
      treated with liver SBRT.

      III. To evaluate explanted irradiated liver tissue (for patients who proceed to liver
      transplantation) to determine extent of residual tumor and extent of radiation effects within
      and around the irradiated field.

      OUTLINE:

      Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of
      unacceptable toxicity.

      After completion of study treatment, patients are followed up at 1, 3, 6, 9, and 12 months
      and then every 6 months for up to 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 7, 2010</start_date>
  <completion_date type="Actual">May 2019</completion_date>
  <primary_completion_date type="Actual">May 9, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severe Treatment-related Toxicity</measure>
    <time_frame>Within 3 months of SBRT</time_frame>
    <description>The percentage of patients who have severe treatment-related toxicity will be computed, along with exact 95% confidence intervals. Severe toxicity will be defined as grade 4 or 5 hepatic toxicity, thrombocytopenia, or gastrointestinal toxicity, graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CSS</measure>
    <time_frame>Time from study entry to death from HCC progression, assessed up to 2 years</time_frame>
    <description>Competing risk analysis will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Time from study entry to death from any cause, assessed up to 2 years</time_frame>
    <description>Estimated by the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate Defined as Proportion of Patients Achieving a Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>Up to 6 months after completion of SBRT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTLP</measure>
    <time_frame>Time from study entry to radiographic local progression based on RECIST, assessed up to 2 years</time_frame>
    <description>Estimated by the Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Adult Hepatocellular Carcinoma</condition>
  <condition>Advanced Adult Hepatocellular Carcinoma</condition>
  <condition>Localized Non-Resectable Adult Liver Carcinoma</condition>
  <condition>Recurrent Adult Liver Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (SBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Radiosurgery</intervention_name>
    <description>Undergo SBRT</description>
    <arm_group_label>Treatment (SBRT)</arm_group_label>
    <other_name>Stereotactic External Beam Irradiation</other_name>
    <other_name>stereotactic external-beam radiation therapy</other_name>
    <other_name>Stereotactic Radiation Therapy</other_name>
    <other_name>Stereotactic Radiotherapy</other_name>
    <other_name>stereotaxic radiation therapy</other_name>
    <other_name>stereotaxic radiosurgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Life expectancy &gt; 3 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2

          -  HCC diagnosed by either of the following approaches:

               -  Histologic confirmation of HCC on biopsy

               -  Evidence of vascular enhancement of suspected lesion on at least two imaging
                  techniques

               -  Evidence of vascular enhancement on a single technique if the alpha-fetoprotein
                  (AFP) is &gt; 200 ng/mL in the setting of cirrhosis or chronic hepatitis B/C

          -  HCC must be deemed unresectable by an experienced surgeon or patient must be medically
             inoperable or extra-hepatic metastases must be present (making resection an
             inappropriate treatment option) or patient must have declined the option of surgery
             after consultation with a surgeon

               -  Barcelona Clinic Liver Cancer score of B or C required (i.e., intermediate or
                  advanced stage HCC)

          -  Prior liver resection or ablative therapy is permitted

          -  Prior transarterial chemoembolization (TACE) is permitted

          -  Patients must have recovered from the effects of previous therapy

          -  Maximal tumor size of 15 cm and &gt; 700 cc of uninvolved liver

          -  Hemoglobin &gt; 9.0 g/L

          -  Absolute neutrophil count &gt;= 1.0 bil/L

          -  Platelets &gt;= 70,000 bil/L

          -  Total bilirubin &lt; 2 mg/dL

          -  International normalized ratio (INR) =&lt; 1.5 or correctable with vitamin K (higher INR
             acceptable if patient is on Coumadin)

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =&lt; 6 times upper
             range of normal

        Exclusion Criteria:

          -  Active hepatitis or encephalopathy related to liver failure

          -  Prior radiation therapy to the upper abdomen or thorax

          -  Lesions within 1 cm from the stomach

          -  Prior uncontrolled, life threatening malignancy within the previous 6 months

          -  Pregnancy is not permitted; women of child-bearing age must undergo pregnancy testing
             prior to enrollment

          -  Previous gastric, duodenal or variceal bleed within the past 2 months

          -  Thrombolytic therapy within 4 weeks or commencement of anticoagulant use within the
             past 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nitin Ohri</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 11, 2013</study_first_submitted>
  <study_first_submitted_qc>July 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2013</study_first_posted>
  <results_first_submitted>December 6, 2019</results_first_submitted>
  <results_first_submitted_qc>January 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2020</results_first_posted>
  <last_update_submitted>January 19, 2020</last_update_submitted>
  <last_update_submitted_qc>January 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Nitin Ohri</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (SBRT)</title>
          <description>Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of unacceptable toxicity.
Stereotactic Radiosurgery: Undergo SBRT</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (SBRT)</title>
          <description>Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of unacceptable toxicity.
Stereotactic Radiosurgery: Undergo SBRT</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="55" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Child-Pugh Score</title>
          <description>The Child-Pugh score employs five clinical measures of liver disease: total bilirubin, serum albumin, prothrombin time, ascites, and hepatic encephalopathy. Each measure is scored 1-3, with 3 indicating most severe derangement. The total score therefore ranges from 5 to 15.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>5</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Severe Treatment-related Toxicity</title>
        <description>The percentage of patients who have severe treatment-related toxicity will be computed, along with exact 95% confidence intervals. Severe toxicity will be defined as grade 4 or 5 hepatic toxicity, thrombocytopenia, or gastrointestinal toxicity, graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0</description>
        <time_frame>Within 3 months of SBRT</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (SBRT)</title>
            <description>Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of unacceptable toxicity.
Stereotactic Radiosurgery: Undergo SBRT</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Treatment-related Toxicity</title>
          <description>The percentage of patients who have severe treatment-related toxicity will be computed, along with exact 95% confidence intervals. Severe toxicity will be defined as grade 4 or 5 hepatic toxicity, thrombocytopenia, or gastrointestinal toxicity, graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CSS</title>
        <description>Competing risk analysis will be performed.</description>
        <time_frame>Time from study entry to death from HCC progression, assessed up to 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS</title>
        <description>Estimated by the Kaplan-Meier method.</description>
        <time_frame>Time from study entry to death from any cause, assessed up to 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate Defined as Proportion of Patients Achieving a Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria in Solid Tumors (RECIST)</title>
        <time_frame>Up to 6 months after completion of SBRT</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TTLP</title>
        <description>Estimated by the Kaplan-Meier method.</description>
        <time_frame>Time from study entry to radiographic local progression based on RECIST, assessed up to 2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (SBRT)</title>
          <description>Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of unacceptable toxicity.
Stereotactic Radiosurgery: Undergo SBRT</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Grade 1 thrombocytopenia</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 1 nausea</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Grade 1 abdominal pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 1 fatigue</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <description>Grade 1 dermatitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nitin Ohri</name_or_title>
      <organization>Montefiore Medical Center and Albert Einstein College of Medicine</organization>
      <phone>718-920-7750</phone>
      <email>nohri@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

